Preview

Современная ревматология

Расширенный поиск

Препараты гиалуроновой кислоты в лечении остеоартроза. Синвиск®(гилан G-F 20): эффективность и безопасность

https://doi.org/10.14412/1996-7012-2013-2444

Полный текст:

Аннотация

Приведены данные о лечении остеоартроза с использованием препаратов гиалуроновой кислоты (ГК), а также о функциях гиалуронана (ГН) в синовиальной жидкости (СЖ), синовиальной ткани и суставном хряще, о различиях в симптом-модифицирующем действии экзогенного ГН с различной молекулярной массой (м. м.) Продемонстрированы преимущества ГН со средней м. м. Показано, что обезболивающий эффект препаратов ГК определяется не только улучшением эласто-вискозных свойств СЖ и защитой болевых рецепторов в тканях сустава, но и наличием у них противовоспалительных свойств.

Об авторе

Наталья Владимировна Чичасова
Кафедра ревматологии ФППОВ ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России
Россия


Литература

1. <div><p>Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumаtol. 2002;14(5):573–7. DOI: http://dx.doi.org/10.1097%2F00002281-200209000-00017.</p><p>Kadam UT, Jordan K, Craft PR. Clinical comorbidity in patients with оsteoarthritis: a case-control study of general practice consulters in England and Walls. Ann Rheum Dis. 2004;63(4):408–14.</p><p>Breivik H, Collett B, Ventafridda V et al. Survey of chronic pain in Europe:</p><p>prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10(4):287–333. Epub 2005 Aug 10. DOI: http://dx.doi.org/10.1016%2Fj.ejpain.2005.06.009.</p><p>Pincus T, Sokka T. Abstract presented during the American College of Rheumatology, 2005. Scientific Sessions. San Diego, California.</p><p>Bateman DN, Kennedy JG. Non-steroidal anti-inflammatory drugs and elderly patients.The medicine may be worse than the disease. BMJ. 1995;310:817–8.</p><p>Ostensen M. Cartilage changes in arthritis do non-steroidal antiphlogistics have positive or negative effects? Tidsskr Nor Laegeforen.1991;111:838–40.</p><p>Haskall VC, Laurent TC. Hyaluronan structure and physical properties. 1997. Available at: //www/glycoforum.gr.jp.scince/hyaluronan/HAO1/HAO1E.html</p><p>Gahl LB, Dahl IMS, Engstrom A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis, 1985;44(12):817–22.</p><p>Balazs EA, Denlinger JL. Viscosupplemetation: a new concept in the treatment of osteoarthritis. J Rheum. 1993;39:3–9.</p><p>Goldenberg VM, Bucwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage. 2005;13(3):216–24.</p><p>Uebelhart D, Williams JM. Effect of hyaluronic acid on cartilage degradation. Curr Opin Rheum. 1999;11(5):427–35. DOI: http://dx.doi.org/10.1097%2F00002281-199909000-00018.</p><p>Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effect molecular weights dependent? Semin Arthr Rheum. 2002;32(10):10–37. DOI: http://dx.doi.org/10.1053%2Fsarh.2002.33720.</p><p>Punzi L. The complexity of the mechanisms of action of hyaluronan in joint diseases. Clin Exp Rheum. 2001;19(3):242–6.</p><p>Takahashi K, Goomer RS, Harwood F et al. The effect of hyaluronan on matrix metalloprotease-3 (MMP-3), interleukin-1 beta(IL-1beta), and tissue inhibitor of metalloprotease-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage. 1999;7(2):182–90.</p><p>Julovi SM, Yasuda T, Shimizu M et al. Inhibition of interleukin-1beta-stimulated production of matrix metalloproteases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum. 2004;50(2):516–25.</p><p>Tetlow LC, Adlam DJ, Wooley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: association with degenerative changes. Arthritis Rheum. 2001;44(3):585–94. DOI: http://dx.doi.org/10.1002%2F1529-0131%28200103%2944%3A3%3C585%3A%3AAID-ANR107%3E3.0.CO%3B2-C.</p><p>Takahashi K, Hashimoto S, Kubo T et al. Effect of hyaluronan on chondrocyte apoptosis and nitric oxide production in experimentally induced osteoarthritis. J Rheumatol. 2000;27(7):1713–20.</p><p>Hulmes DJ, Marsden ME, Strachan RK et al. Intra-articular hyaluronate in experimental rabbit osteoarthritis can prevent changes in cartilage proteoglycan content. Osteoarthritis Cartilage. 2004;12(3):232–8. DOI: http://dx.doi.org/10.1016%2Fj.joca.2003.11.007.</p><p>Corrado EM, Peluso GF, Gigliotti S et al. The effects of intraarticular administration of hyaluronic acid on osteoarthritis of the knee: a clinical study with immunological and biochemical evaluations. Eur J Rheum Infl. 1995;15:47–56.</p><p>Lisignoli G, Grassi F, Zani N et al. Anti-Fas-induced apoptosis in chondrocytes reduced by hyaluronan. Arthritis Rheum. 2001;44(8):1800–7. DOI: http://dx.doi.org/10.1002%2F1529-0131%28200108%2944%3A8%3C1800%3A%3AAID-ART317%3E3.0.CO%3B2-1.</p><p>Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodiumhyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage. 1993;1(2):97–103. DOI: http://dx.doi.org/10.1016%2FS1063-4584%2805%2980024-X .</p><p>Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol. 1998;25(11):2203–12.</p><p>Huskisson EC, Donnely S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford). 1999;38(7):602–7. DOI: http://dx.doi.org/10.1093%2Frheumatology%2F38.7.602.</p><p>Puhl W, Bernau A, Greiling H et al. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthritis Cartilage. 1993;1(4):233–41. DOI: http://dx.doi.org/10.1016%2FS1063- 4584%2805%2980329-2.</p><p>Brandt KD, Block JA, Mishalski JP et al. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHO-VISC Study Group. Clin Orthop Relat Res. 2001;(385):130–43.</p><p>Lohmander LS, Dalen N, Englund G et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicenter trial. Ann Rheum Dis. 1996;55(7):424–31. DOI: http://dx.doi.org/10.1136%2Fard.55.7.424.</p><p>Barrett JP, Siviero P. Retrospective study of outcomes in Hyalgan-treated patients with osteoarthritis of the knee. Clin Drug Investing. 2002;22(2):87–97. DOI: 10.2165/00044011-200222020-00003.</p><p>Lussier A, Cividino AA, McFarlane CA et al. Viscosupplemetation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. 1996;23(9):1579–85.</p><p>Kazimir J, Simkanin P, Bancziova E et al. Hyalgan in the treatment of osteoarthritis. A postmarketing study, January – June 1998. Rehabilit. 1998;31.</p><p>Shimizu C, Kubo T, Hirasawa Y et al. Histimorphometric and biochemical effect of various hyaluronans on early osteoarthritis. J Rheumatol. 1998;25(9):1813–9.</p><p>Kukuchi T, Yamada H, Shimmer M. Effect of high molecular weight hyaluronan on cartilage degradation in a rabbit model of osteoarthritis. Osteoarthritis Cartilage. 1996;4(2):99–110.</p><p>Vitanzo PC, Sennett BJ. Hyaluronans: is clinical effectiveness dependent on molecular weight. Am J Orthop (Belle Mead NJ). 2006;35(9):421–8.</p><p>Undqvist U, Tolmachev V, Kalremo K et al. Elimination of stablised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41(8):603–13.</p><p>Lindenhayan K, Hellman HH, Nederhausen T et al. Elimination of tritium-labelled hyaluronic acid from normal and osteoarthritic rabbit knee joints. Eur J Clin Chem Clin Biochem. 1997;35(5):355–63. DOI: http://dx.doi.org/10.1515%2Fcclm.1997.35.5.355.</p><p>Brown T, Laurent U. Turnover of hyaluronan in synovial joints: elimination of labeled hyaluronan from the knee joint of rabbit. Exp Physiol. 1991;76(1):125–34.</p><p>Cubukcu D, Ardic F, Karabulut N, Topuz O. Hylan GF 20 efficacy on articular cartilage quality in patients with knee osteoarthritis: clinical and MRI assessment. Clin Rheumatol. 2005;24(4):336–41. Epub 2004 Dec 14.</p><p>Seale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritis knees with hyalgan: A treatment schedule study. Curr Ther Res. 1994;55:220–32.</p><p>Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial on efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410–23. DOI: http://dx.doi.org/10.1016%2FS0149-2918%2898%2980052-0.</p><p>Chevalier X, Jerosch J, Goupille P et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicenter, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69(1):113–9. DOI: 10.1136/ard.2008.094623.</p><p>Conrozier T, Jerosch J, Beks P et al. Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation wih hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study. Arch Orthop Trauma Surg. 2009 Mar;129(3):417–23. DOI: 10.1007/s00402-008-0601-2. Epub 2008 Mar 26.</p><p>Wobig M, Bach G, Beks P et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther. 1999;21:1549–62. DOI: http://dx.doi.org/10.1016%2FS0149-2918%2800%2980010-7.</p><p>Raman R, Duta A, Day N et al. Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatment of osteoarthritis of the knee – a prospective randomized clinical trial. Knee. 2008;15:318–24. DOI: 10.1016/j.knee.2008.02.012. Epub 2008 Apr 21.</p><p>Rarlsson J, Sjogren LS, Lohmaner LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicenter study. Rheumatology (Oxford). 2002;41(11):1240–8.</p><p>Bellamy N, Campbell J, Robinson V et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;19(2):CD005321.</p><p>Raynauld JP, Torrance GW, Band PA et al.; Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into to treatment paradigm for patients with knee osteoarthritis (Part1 of 2): clinical results. Osteoarthritis Cartilage. 2002;10(7):506–17.</p><p>Caborn D, Rush JL, Lanzer W et al. A randomized single blind comparison of the efficacy and tolerability of Hylan GF-20 and triamcinolone hexaacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004;31(2):333–43.</p><p>Yustin D, Kryshtalskyj B, Galea A. Use of Hylan G-F 20 for viscosupplementation of the temporomandibular joint for the management of osteoarthritis: a case report. J Orofac Pain. 1995;9(4):375–9.</p><p>Figen Ayhan F, Ustin N. The evaluation of efficacy and tolerability of Hylan G-F 20 in bilateral; thumb base osteoarthritis: 6 months follow-up. Clin Rheumatol. 2009;28(5):535–41. DOI: 10.1007/s10067-008-1080-0. Epub 2009 Jan 10.</p><p>Mandl LA, Hotchkiss RM, Adler RS et al. Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial. Curr Med Res Opin. 2009;25(9):2103–8. DOI: 10.1185/03007990903084016.</p><p>Wang Y, Hall S, Hanna F. Effect of hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMS Muskuloskelet Disord. 2011;12:195–203. DOI: 10.1186/1471-2474-12-195.</p><p>Frizziero L, Govoni E, Bacchini P. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. Clin Exp Rheumatol. 1998;16(4):441–9.</p><p>Listrat V, Ayral X, Patarnello F et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage. 1997;5(3):153–60. DOI: http://dx.doi.org/10.1016%2FS1063-4584%2897%2980010-6.</p><p>Jubb RW, Piva S, Beinat L et al. A one-year, randomised, placebo (saline) controlled trial of 530-700 kDda sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract. 2003;57:467–74.</p><p>Wluka AE, Wolfe R, Stuckey S, Cicuttini FM. How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis? Ann Rheum Dis. 2004;63(3):264–8. DOI: http://dx.doi.org/10.1136%2Fard%2F2003.007666.</p><p>Cicuttini FM, Jones G, Forbes A et al. Rate of cartilage loss at two years predicts sub sequent total knee arthroplasty: a prospective study. Ann Rheum Dis. 2004;63(9):1124–7. Epub 2004 Apr 28.</p><p>Migliori A, Bizzi E, Massafra U et al. The impact of treatment with Hylan G-F 20 on progression to total hip arthroplasty in patients with symptomatic hip OA: a retrospective study. Curr Med Res Opinion. 2012;28(5):755–60. DOI: 10.1185/03007995.2011.645563. Epub 2012 Apr 18.</p><p>Pullman-Mooar S, Mooar P, Sieck M et al. Are there distinctive inflammatory flares of synovitis after hylan GF intraarticular injections? J Rheumatol. 2002 Dec;29(12):2611–4.</p><p>Puttic MP, Wade JP, Chalmers A et al. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol. 1995;22(7):1311–4.</p><p>Bernardeu C, Bucki B, Liote F. Acute arthritis after intraarticular hyaluronate injection: onset of effusion without crystal. Ann Rheum Dis. 2001;60(5):518–20.</p><p>Bucher W, Otto T, Hamburger MI. Differentiation of hyaluronate products by qualitative difference in their immunogenicity in rabbits: a possible mechanism for productspecific severe adverse reaction? Arthritis Rheum. 2002;46(9):2543–4. DOI: http://dx.doi.org/10.1002%2Fart.10450.</p><p>Kahan A, Leu P-L, Salin A. Prospective randomized study comparing the medicoeconomic benefits of Hylan GF-20 vs. conventional treatment in knee osteoarthritis. Joint Bone Spine. 2003;70(4):276–81. DOI: http://dx.doi.org/10.1016%2FS1297-319X%2803%2900043-5.</p><p>Palm T, van der Heijde D, Altman RD. Outcome variables for osteoarthritis clinical trials. J Rheumatol. 2003;30(7):1648–54.</p></div><br />


Для цитирования:


Чичасова Н.В. Препараты гиалуроновой кислоты в лечении остеоартроза. Синвиск®(гилан G-F 20): эффективность и безопасность. Современная ревматология. 2013;7(4):85-91. https://doi.org/10.14412/1996-7012-2013-2444

For citation:


Chichasova N.V. Hyaluronic acid preparations in the treatment of osteoarthritis. Synvisk®(Hylan G-F 20): Efficacy and safety. Modern Rheumatology Journal. 2013;7(4):85-91. (In Russ.) https://doi.org/10.14412/1996-7012-2013-2444

Просмотров: 1946


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)